TOBI®: PROVEN IN CF TO EFFECTIVELY TARGET Pa IN THE LUNGS1

TOBI reaches infected lungs through its unique formulation and particle size2


To effectively fight Pa, TOBI needs to reach the infection in the lungs. The optimal particle size of an inhaled antibiotic to accomplish this is in the range of 1 µm to 5 µm.2

 

The PARI LC® Plus Reusable Nebulizer and the DeVilbiss® Pulmo-Aide® air compressor produce aerosols of TOBI with an MMAD* between 2 and 4 µm.3 This helps TOBI reach the site of the infection.2

Percentage of CF patients infected with Pa at different age intervals
  • TOBI has bactericidal activity against Pa1
  • In vitro, TOBI reduced Pa biofilm formation by 97% (P<.05) and reduced established biofilm mass by 64% (P<.05). TOBI was used at 1000 μg/mL, the peak concentration measured in the BAL† isolated from the lungs of CF patients4‡

*Mass median aerodynamic diameter.

†Bronchoaveolar lavage.

‡The clinical relevance of this finding has not been established.1

 
Important Safety Information full Prescribing Information www.fda.gov/medwatch

References:

  • TOBI [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2009.
  • Asmus MJ, Milavetz G, Tice AL, Teresi ME. In vitro characteristics of tobramycin aerosol from ultrasonic and jet nebulizers. Pharmacotherapy. 2001;21(5):534-539.
  • de Boer AH, Hagedoorn P, Frijlink HW. The choice of a compressor for the aerosolisation of tobramycin (TOBI®) with the PARI LC PLUS® reusable nebulizer. Int J Pharm. 2003;268:59-69.
  • Moreau-Marquis S, O'Toole GA, Stanton BA. Tobramycin and FDA-approved iron chelators eliminate Pseudomonas aeruginosa biofilms on cystic fibrosis cells. Am J Respir Cell Mol Biol. 2009;41:305-313.